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Fecal incontinence is an embarrassing social problem to the patients affect-
ing patients’ work and social ordinary life. It affects both sexes characterized by 
inability to control bowel motions causing leaking stool or flatus unexpectedly 
from the rectum and anus, and in severe cases, it causes a complete loss of bowel 
control. The causes are severe diarrhea, constipation, muscle and nerve damage 
that is caused by aging, vaginal delivery, episiotomy or forceps delivery. Anal and 
rectal continence depends on many aspects like consistency of stool, neuromuscular 
sphincter complex, rectal capacity, sensation of defecation and ability to move and 
reach a toilet. Another cause is immunological disorders that cause muscle damage 
due to formation of autoantibodies in autoimmune diseases or in association with 
gastrointestinal manifestation of autoimmune diseases like multiple scleroses and 
other autoimmune diseases. Simply, it can be diagnosed by routine digital rectal 
examination that has good sensitivity and poor specificity in discriminating small 
from severe anal sphincter defects.
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1. Introduction
Fecal incontinence is an embarrassing social problem to the patients affecting 
patients’ quality of life. It affects both sexes (males and females) characterized 
by inability to control bowel motions causing leaking stool unexpectedly from 
the rectum while passing gases and sometimes a complete loss of bowel control 
[1]. This condition caused by diarrhea, constipation, muscle damage and nerve 
damage that caused either by aging or vaginal delivery. Thus fecal continence 
depends on many factors like consistency of fecal substance, neuromuscular 
sphincter complex, rectal capacity, sensation of defecation and ability to move 
and reach a toilet [2]. Another cause is immunological disorders that cause 
muscle damage due to formation of autoantibodies in autoimmune diseases [3]. 
Simply it can be diagnosed by routine digital rectal examination that had good 
sensitivity and poor specificity in discriminating small from severe global anal 
sphincter defects [4].
2. What is autoimmunity?
Autoimmunity is a disorder of the immune system characterized by absence 
of immune tolerance (Tolerance is absence of immune response in immune 
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competence person) whether central tolerance in the thymus or peripheral through 
Treg cell CD4 + CD25 + (T regulatory). It is due to a defect in immune regulatory 
and signaling mechanisms, genetic factors like single-gene defects or gene mutation 
can cause an immune dysregulation and autoimmunity [5].
3. Causes of autoimmunity
It was caused by interaction of environmental that augment activation of self-
reactive lymphocytes which escaped control in the thymus and are react against 
self-constituents antigens and genetic factors that mentioned below:
3.1 Epigenetic alteration
Epigenetic alterations like DNA methylation, histone modification, and 
microRNAs that alter the transcription and activity of genes that are involved in 
autoimmune responses and diseases pathogenesis. These leads to aberrant epigen-
etic modifications in CD4 T helper cells function through deregulations in several 
transcriptional genes like Ifng, Cd70, Tnf, Dnmt3a, and Foxp3 that determine T-cell 
identity. Adding to that, epigenetics target regulatory genes like Tim-3, cereblon, 
protein kinase C theta, octamer transcription factor 1, basic leucine zipper tran-
scription factor ATF-like, p70 kinase, and lactate dehydrogenase A that influence 
T-cell activation, differentiation, and metabolism [6].
3.2 Genetic mutation in inflammasomes
Inflammasomes can be defined as multi-protein complexes consisting of NOD-
like receptor (NLR)/an AIM-like receptor (ALR), apoptosis-associated speck-like 
protein that contains a CARD and caspase-1. The active caspase-1 cleaves pro-
IL-1β and pro-IL-18 to IL-1β and IL-18, resulting in inflammation. Genetic muta-
tions in inflammasomes result in autoimmune diseases. NOD-like receptor family, 
pyrin domain containing 1 (NLRP1) haplotypes contributes to susceptibility to 
autoimmune disease and single nucleotide polymorphisms (SNPs) that alters the 
susceptibility and severity of autoimmune disease. IL-1β and IL-18 maintain Th17 
responses and endothelial cell damage, which potentiate autoimmune diseases. 
Autoimmunity is mediated in part by innocent bystander cells, augmented by 
inflammasomes [7].
3.3 HLA-associated autoimmune disease
Autoimmune diseases had an associations with particular HLA alleles through 
displaying the autoantigens targeted by self-reactive T cells that escape thymic 
deletion because most HLA alleles are capable of presenting self-antigens even in 
healthy individuals [8].
3.4 Cytokines pathway
Cytokine and cytokine receptor genetic polymorphisms have been associated 
with many different autoimmune diseases like IL23R and IL-23 that augments the 
proinflammatory action of Th17 cells that leads to tissue damage and anticytokines 
therapy can be nicely used as target to treat autoimmune diseases [9–11].
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4. Mechanism of autoimmunity
The mechanism of autoimmune reactions is due to an imbalance between two 
immune responses effector and regulatory that develop through stages of initiation 
and propagation, and often show phases of resolution or remissions and exacerba-
tions or flares. The mechanism of autoimmunity is defective elimination and or 
control of self-reactive lymphocytes. A major goal of treatment is reestablishing the 
normal balance between effector and regulatory immune responses [12] (Figure 1).
5. Gastrointestinal manifestations in systemic autoimmune diseases
The systemic autoimmune diseases include different diseases like collagen vas-
cular diseases, systemic vasculitides, Wegener granulomatosis and Churg-Strauss 
syndrome that involve any part of gastrointestinal tract, hepatobiliary system and 
pancreas. Patients with these diseases had different gastrointestinal symptoms like 
oral ulcers, dysphagia, gastroesophageal reflux diseases, abdominal pain, constipa-
tion, diarrhea, fecal incontinence, pseudo-obstruction, perforation of GIT tract and 
bleeding [13].
5.1 Effects of autoimmune diseases on the gastrointestinal tract
Autoimmune disease characterized by autoreactive T cells attacking body’s 
own tissues. Gastrointestinal manifestations are either initial presentation or late 
complications of the disease.
5.1.1 Systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is an autoimmune disease of unknown 
etiology, characterized by deposition of autoantibodies and immune complexes 
in tissues (Type III hypersensitivity). Gastrointestinal manifestations of SLE 
are due to primary gastrointestinal disorders, complications of therapy and SLE 
Figure 1. 
Mechanism of autoimmunity.
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itself. Any part of the gastrointestinal tract may become involved in SLE. Many 
GI conditions can be mimicked by SLE [14]. Lupus enteritis defines as alimen-
tary tract lesions in SLE. The manifestations include oral mucosal ulcers and 
decreased salivation occurring in the hard palate, buccal mucosa, dysphagia, 
esophageal ulceration, gastric ulceration, pseudo-obstruction and fecal incompe-
tence [15–17].
5.1.2 Rheumatoid arthritis
It is also type III hyper sensitivity reaction due to deposition of immune com-
plexes in the synovium of small interphalangeal joints of the hands. Gastrointestinal 
manifestations are common and variable. It involved esophagus that decreased 
peristalsis, decreased lower esophageal sphincter tone, hiatal hernia, esophageal 
ulcer, peptic ulcer, chronic atrophic gastritis, colonic inflammation like collagenous 
colitis and fecal incompetence with secondary amyloidosis may occur [18].
5.1.3 Sjogren’s syndrome
Sjogren’s syndrome is a common autoimmune disease due to B cell activation and 
invasion of T and B lymphocytes to affected exocrine glands. This disease affect the 
gastrointestinal tract like dry mouth, difficulty in swallowing, esophageal atrophy, 
epigastric pain, dyspepsia, chronic atrophic gastritis, chronic pancreatitis, jejunitis, 
sigmoiditis, and inflammatory bowel disease [19, 20].
5.1.4 Progressive systemic sclerosis(scleroderma)
It is one of the connective-tissue disease of unknown etiology that affects 
females more than males. It is characterized by vasculopathy, tissue fibrosis 
and autoimmunity. It causes overproduction of collagen due to autoimmune 
dysfunction that leads to fibrosis of many visceral organs. The immune system 
attacks the kinetochore of the chromosomes that lead to genetic malformation 
of nearby genes. Patients had gastrointestinal tract symptoms like thinning of 
the lips, tightening of the perioral skin, impaired taste sensation, atrophy of 
the mucous membrane and tongue papilla, dysphagia and dyspepsia, gastro-
esophageal reflux, peptic esophagitis, Barrett’s metaplasia, gastric antral vascular 
ectasia (GAVE) or watermelon stomach, dysmotility of small intestine may cause 
chronic pseudo-obstruction. As scleroderma progresses leads to decreased motil-
ity of the intestine and leads to progressive fibrosis and scarring of the small 
intestine leading to bacterial overgrowth and malabsorption of nutrients and 
growth in stagnant intestinal fluid. Large intestine and colon will be involved 
causing pseudo-obstruction or ischemic colitis [21, 22]. Anorectal involvement 
causes fecal incontinence and rectal prolapse. GIT involvement greatly affects 
morbidity and mortality in this disease and therapy aim to relieve these symp-
toms [23, 24].
5.1.5 Polyarteritis nodosa
The gastrointestinal manifestations of systemic vasculitis that results from 
mesenteric ischemia are vague non specific abdominal pain, hematemesis, 
melena, hematochezia, jejunal ulceration and perforation. Liver may be 
involved with acalculous cholecystitis, appendicitis, pancreatitis and biliary 
strictures [25–27, 36].
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5.1.6 Kawasaki disease
It is a syndrome that characterized by oral mucosal changes, exanthem, enan-
them, fever, lymphadenopathy, and polyarteritis in addition to gastrointestinal 
symptoms like abdominal pain, vomiting, diarrhea, small bowel obstruction, 
jaundice and paralytic ileus [28].
5.1.7 Inflammatory muscle disorders: polymyositis and dermatomyositis
This is a systemic autoimmune diseases characterized by inflammation of 
striated and smooth muscle of the body. Patients had a progressive weakness of 
proximal striated muscles, skin rash with dermatomyositis. The whole gastrointes-
tinal tract may be affected but the proximal esophagus is more common affected. 
Gastric and esophageal emptying and peristalsis is affected in many patients, so 
they complain of dysphagia, aspiration, nasal regurgitation, early satiety, bloating, 
reduced gastrointestinal motility, hiatal hernia, gastroesophageal reflux disease 
(GERD), stricture, dilated atonic esophagus associated with delayed gastric 
emptying and intestinal mucosal thickening. In addition to that, there are colonic 
pseudodiverticula, pneumatosis, and constipation. Neurological dysfunction and 
diminished smooth muscle contractility due to muscle atrophy, fibrosis and inflam-
mation leading to wall edema, ulceration and perforation [29].
5.1.8 Giant cell arteritis
It is a granulomatous inflammation of the arteries particularly cranial and 
temporal leads to narrowing the lumen of the arteries. The main symptoms are 
headache, fever, increased erythrocyte sedimentation rate and blindness occurring 
suddenly associated with intestinal manifestation like gangrene, acute pancreatitis, 
liver granulomas, lymphocytic infiltration, dilated bile canaliculi, and hepatocel-
lular [30, 31].
5.1.9 Henoch-Schönlein purpura
It is an IgA mediated immune complex deposits resulting in systemic vasculitis in 
small vessels. Gastrointestinal signs and symptoms are common presenting symp-
tom like periumbilical pain with nausea and vomiting. Some times ulceration of the 
mucosa of the second part of the duodenum and less in colon and rectum [32].
5.1.10 Takayasu arteritis
It is a chronic vasculitis of unknown etiology. The inflammatory processes 
cause thickening, narrowing, and occluding of the walls of the affected arteries. 
Patients usually complaining from gastrointestinal symptoms due to the involve-
ment of the descending abdominal aorta like abdominal pain, nausea, diarrhea and 
hemorrhage [33].
5.1.11 Cogan’s syndrome
It is a chronic inflammatory disorder characterized by interstitial keratitis, 
audiovestibular system involvement, aortitis, mesenteric vasculitis, weight 
loss, fever, lymphadenopathy, hepatosplenomegaly, abdominal pain, nausea, 
vomiting [34].
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5.1.12 Churg-Strauss syndrome
It is an allergic angiitis occurs mostly in asthmatic patients associated with 
granulomatous necrotizing vasculitis. Patients had eosinophilia, fever, and aller-
gic rhinitis and sometimes gastrointestinal involvement occurs in about 50% of 
patients leading to eosinophilic gastroenteritis associated with abdominal pain, 
bloody diarrhea due to multiple ulcers, nausea and vomiting. Perforation of the 
small intestine and colon commonly occurs. Necrotizing granulomatous vasculitis 
of the mesenteric artery leads to mucosal ischemia [35].
5.1.13 Wegener granulomatosis
It is a systemic autoimmune disease characterized by granulomatous vasculitis of 
the upper and lower respiratory tracts infection, glomerulonephritis, and small-vessel 
necrotizing vasculitis with granuloma formation. Gastrointestinal manifestations 
of Wegener granulomatosis are oropharyngeal mucosal lesions, gingivitis, ulcer of 
gastric mucosa, small intestinal perforation, colonic ulceration, non healing perianal 
ulcers, cholecystitis, recurrent acute pancreatitis and splenic necrosis [25, 36].
5.1.14 Antiphospholipid antibody syndrome
It is a disorder characterized by recurrent vascular thrombosis, abortion and 
thrombocytopenia, increased antiphospholipid antibodies. The gastrointestinal 
manifestations of antiphospholipid antibody syndrome leads to vasculopathy and 
tissue ischemia. Antiphospholipid antibodies in SLE patients are associated with Budd-
Chiari syndrome presenting with abdominal pain, ascites and hepatic failure [37–39].
5.1.15 Spondyloarthropathies
They are a group of interconnected chronic inflammatory rheumatic diseases 
including ankylosing spondylitis, arthritis associated with inflammatory bowel 
disease and reactive arthritis. The spondyloarthropathies are associated with the 
HLA-B27 gene. About 36% of patients had reactive arthritis secondary to a dysen-
teric infection were positive for HLA-B27. Subclinical gut inflammation, ulcerative 
colitis and Crohn’s disease are frequent types of idiopathic IBD that are associated 
with arthritis or spondylitis [40–44].
5.1.16 Behçet’s disease
It is a widespread autoimmune vasculitis of unknown origin occurring in all ages 
resulting in a damage to blood vessels in all the body. Patients usually had uveitis with 
oral and genital ulcers. Clinical manifestations also include vascular, neurological, articu-
lar, renal and gastrointestinal manifestations. Regarding gastrointestinal Behçet’s disease 
symptoms which is difficult to differentiate it from inflammatory diseases are nausea, 
abdominal pain, bloody diarrhea, ulceration in mouth, gastrointestinal tract or genetal 
which is painful, shallow, round with discrete borders. Segmental mucosal ulceration in 
the ileocecal and colonic area leads to perforation and bloody diarrhea [45].
6. Conclusions
It had been found that fecal incompetence which is due to muscle damage that 
make anal sphincter difficult to hold stool properly after birth, episiotomy or 
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forceps. Other cause is nerve damage that due to nerve injury that affect sense stool 
in the rectum or anus which is due to childbirth, spinal cord injury, stroke, diabetes 
and multiple sclerosis that cause nerve damage. It can also be occur either due to 
autoimmune diseases or due to administration of medications like certain immuno-
modulators or immunosuppressive drugs.
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